Type
PatentPatent Status
Granted PatentKAUST Department
Computational Bioscience Research Center (CBRC)Technology Transfer
Date
2014-04-17Submitted Date
2013-03-13Permanent link to this record
http://hdl.handle.net/10754/594844
Metadata
Show full item recordAbstract
Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative `A` (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative `A` was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative `A` could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative `A` highlights its possible role as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic drugsPatent Number
US9890106B2Application Number
US 20140107196 A1Additional Links
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140107196%22.PGNR.&OS=DN/20140107196&RS=DN/20140107196http://assignment.uspto.gov/#/search?adv=publNum:20140107196
http://www.google.com/patents/US20140107196
http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2014107196A1&KC=A1&FT=D